First Time Loading...

Globus Medical Inc
NYSE:GMED

Watchlist Manager
Globus Medical Inc Logo
Globus Medical Inc
NYSE:GMED
Watchlist
Price: 63.97 USD -1.05% Market Closed
Updated: May 13, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

4.9B
-3%
Assets
Growth Rates:
1 Year
+130%
3 Years
+184%
5 Years
+270%
7 Years
+415%
10 Years
+725%
1B
-6%
Liabilities
Growth Rates:
1 Year
+335%
3 Years
+484%
5 Years
+935%
7 Years
+1 016%
10 Years
+949%
3.9B
-2%
Equity
Growth Rates:
1 Year
+105%
3 Years
+151%
5 Years
+217%
7 Years
+351%
10 Years
+681%

Balance Sheet Decomposition
Globus Medical Inc

4.9B
Assets
1B
Liabilities
4.9B
Assets
1B
Liabilities
Current Assets 1.8B
Cash & Short-Term Investments 434.5m
Receivables 534.7m
Other Current Assets 859.4m
Non-Current Assets 3.1B
Long-Term Investments 51.3m
PP&E 635.9m
Intangibles 2.3B
Other Non-Current Assets 88.6m
Current Liabilities 786.3m
Accounts Payable 50.5m
Accrued Liabilities 221.4m
Other Current Liabilities 514.5m
Non-Current Liabilities 234.9m
Long-Term Debt 298k
Other Non-Current Liabilities 234.6m

Balance Sheet
Globus Medical Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
82
60
133
119
140
196
239
193
151
467
Cash Equivalents
82
60
133
119
140
196
239
193
151
467
Short-Term Investments
146
221
158
255
200
116
187
250
296
50
Total Receivables
81
86
96
127
144
162
148
166
217
505
Accounts Receivables
75
78
92
117
137
154
142
164
213
503
Other Receivables
6
9
4
10
7
8
6
1
4
2
Inventory
91
105
113
108
131
196
229
237
299
848
Other Current Assets
69
72
15
11
15
17
18
18
21
45
Total Current Assets
470
545
514
620
631
688
822
865
983
1 915
PP&E Net
70
115
124
143
172
202
222
226
244
648
PP&E Gross
70
115
124
143
172
202
222
226
244
648
Accumulated Depreciation
119
139
167
192
217
244
277
306
343
426
Intangible Assets
35
33
62
79
87
79
87
69
64
925
Goodwill
53
92
106
124
124
129
157
180
198
1 435
Note Receivable
0
0
30
28
0
0
0
0
0
0
Long-Term Investments
75
49
60
56
263
410
359
563
496
75
Other Long-Term Assets
1
1
32
28
24
25
34
56
92
88
Other Assets
53
92
106
124
124
129
157
180
198
1 435
Total Assets
704
N/A
834
+19%
928
+11%
1 079
+16%
1 301
+21%
1 532
+18%
1 680
+10%
1 957
+17%
2 076
+6%
5 086
+145%
Liabilities
Accounts Payable
21
16
18
25
26
25
18
22
36
57
Accrued Liabilities
62
54
46
53
60
63
78
91
95
252
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
Other Current Liabilities
7
13
16
15
10
24
24
27
28
83
Total Current Liabilities
89
83
80
93
96
111
121
140
159
392
Long-Term Debt
0
0
0
0
0
0
0
0
0
418
Deferred Income Tax
5
13
8
11
8
6
6
4
2
84
Other Liabilities
24
23
8
7
11
12
46
71
69
194
Total Liabilities
118
N/A
119
+1%
96
-20%
111
+16%
115
+4%
130
+13%
173
+34%
216
+25%
230
+6%
1 088
+374%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
Retained Earnings
412
525
629
736
893
1 048
1 045
1 194
1 240
1 137
Additional Paid In Capital
175
193
212
238
300
357
457
554
631
2 871
Unrealized Security Profit/Loss
0
0
0
0
0
4
5
1
15
2
Other Equity
2
2
9
7
7
7
1
6
10
8
Total Equity
586
N/A
715
+22%
832
+16%
968
+16%
1 186
+22%
1 403
+18%
1 506
+7%
1 741
+16%
1 846
+6%
3 998
+117%
Total Liabilities & Equity
704
N/A
834
+19%
928
+11%
1 079
+16%
1 301
+21%
1 532
+18%
1 680
+10%
1 957
+17%
2 076
+6%
5 086
+145%
Shares Outstanding
Common Shares Outstanding
95
95
96
97
99
100
100
102
100
136

See Also

Summary
GMED intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMED stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMED stock valuation using valuation multiples.
Wall Street Estimates
GMED price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMED stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.